These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31932846)

  • 1. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
    Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
    Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
    Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
    Front Immunol; 2020; 11():584520. PubMed ID: 33542712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
    Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
    J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
    Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
    N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
    Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
    Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor
    Schetelig J; Baldauf H; Heidenreich F; Hoogenboom JD; Spellman SR; Kulagin A; Schroeder T; Sengeloev H; Dreger P; Forcade E; Vydra J; Wagner-Drouet EM; Choi G; Paneesha S; Miranda NAA; Tanase A; de Wreede LC; Lange V; Schmidt AH; Sauter J; Fein JA; Bolon YT; He M; Marsh SGE; Gadalla SM; Paczesny S; Ruggeri A; Chabannon C; Fleischhauer K
    Front Immunol; 2024; 15():1350470. PubMed ID: 38629074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
    Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.
    Sobecks RM; Wang T; Askar M; Gallagher MM; Haagenson M; Spellman S; Fernandez-Vina M; Malmberg KJ; Müller C; Battiwalla M; Gajewski J; Verneris MR; Ringdén O; Marino S; Davies S; Dehn J; Bornhäuser M; Inamoto Y; Woolfrey A; Shaw P; Pollack M; Weisdorf D; Milller J; Hurley C; Lee SJ; Hsu K
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1589-96. PubMed ID: 25960307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
    Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
    Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
    Hoseinian SA; Jafari D; Mahmoodi M; Alimoghaddam K; Ostadali M; Talebzadeh Bonakdar A; Foma AM; Yekaninejad MS; Amirzargar AA
    Turk J Med Sci; 2018 Aug; 48(4):794-804. PubMed ID: 30119155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.
    Mancusi A; Ruggeri L; Urbani E; Pierini A; Massei MS; Carotti A; Terenzi A; Falzetti F; Tosti A; Topini F; Bozza S; Romani L; Tognellini R; Stern M; Aversa F; Martelli MF; Velardi A
    Blood; 2015 May; 125(20):3173-82. PubMed ID: 25769621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].
    Liang ZY; Ren HY; Cen XN; Qiu ZX; Wang LH; Ou JP; Li Y; Wang MJ; Wang WS; Xu WL; Dong YJ; Yin Y; Sun YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):155-60. PubMed ID: 23484711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
    Shimoni A; Vago L; Bernardi M; Yerushalmi R; Peccatori J; Greco R; Shem-Tov N; Lo Russo A; Danylesko I; Apel A; Bonini C; Lupo Stanghellini MT; Nagler A; Ciceri F
    Am J Hematol; 2017 Oct; 92(10):1011-1019. PubMed ID: 28631269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.
    Rogatko-Koroś M; Mika-Witkowska R; Bogunia-Kubik K; Wysoczańska B; Jaskuła E; Kościńska K; Nestorowicz K; Dziopa J; Szlendak U; Gwozdowicz S; Graczyk-Pol E; Lange A; Nowak J
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):63-71. PubMed ID: 27933342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML.
    Shaffer BC; Le Luduec JB; Park S; Devlin S; Archer A; Davis E; Cooper C; Nhaissi M; Suri B; Wells D; Tamari R; Papadopoulos E; Jakubowski AA; Giralt S; Hsu KC
    Blood Adv; 2021 Apr; 5(7):2003-2011. PubMed ID: 33843984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
    Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
    J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor KIR Genotype Impacts on Clinical Outcome after T Cell-Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients.
    Escudero A; Martínez-Romera I; Fernández L; Valentín J; González-Vicent M; Vicario JL; Madero-Jarabo R; Diaz MÁ; Pérez-Martínez A
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2493-2500. PubMed ID: 30145228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.